3 Risks Amarin Still Faces After Its Huge FDA Win for Vascepa

Sure, there was a little intrigue along the way. But the outcome that pretty much everyone expected arrived: Amarin (NASDAQ: AMRN) won FDA approval of a key label expansion for Vascepa. The drug, first approved in 2012 for lowering triglyceride levels, is now also approved to reduce cardiovascular risk.

Amarin's shares soared on last week's FDA decision. Sales of Vascepa are sure to soar very soon. Plenty of observers (including yours truly) anticipate that Amarin could become an acquisition target.

But don't think that Amarin is totally out of the woods. The biotech still faces three key risks after its huge FDA win for Vascepa.

Continue reading

Source Fool.com